Want to see AU:CSL full AI Analyst Report?
CSL Stock Chart & Stats
AU$173.64
AU$2.17(1.90%)
At close: 4:00 PM EDT
AU$173.64
AU$2.17(1.90%)
Day’s Range― - ―
52-Week RangeAU$90.00 - AU$221.76
Previous CloseN/A
Volume639.54K
Average Volume (3M)1.14M
Market Cap
AU$94.20B
Enterprise ValueAU$70.67B
Total Cash (Recent Filing)AU$1.51B
Total Debt (Recent Filing)AU$10.89B
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Feb 09, 2027EPS Estimate
5.78Next Dividend Ex-DateN/A
Dividend Yield2.07%
Share Statistics
EPS (TTM)-5.29
Shares Outstanding479,884,280
10 Day Avg. Volume1,026,353
30 Day Avg. Volume1,139,177
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.74
Price to Sales (P/S)3.45
P/FCF Ratio18.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$183.75Price Target Upside5.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)6.17
Revenue Forecast (FY)AU$15.75B
Bulls Say, Bears Say
Bulls Say
Cash GenerationStrong operating cash flow despite a statutory loss demonstrates that the core business continues to convert operations into funding. This supports investment, dividends and buybacks while giving management flexibility to absorb restructuring costs and pursue longer-term growth initiatives.
Transformation SavingsSavings delivered ahead of plan provide a tangible avenue to protect earnings and improve efficiency over the next several periods. Reinvesting part of the benefits into commercial and R&D activity could also strengthen productivity and support the company’s competitive position.
Ig Growth And Product MomentumImproving immunoglobulin momentum and successful specialty-product launches reinforce CSL Behring’s role as a durable growth engine. Broader adoption of newer therapies can improve the product mix, diversify revenue and help offset pressure affecting more mature products.
Bears Say
Impairments And Statutory LossThe scale of impairments and the statutory loss materially weaken reported earnings quality and reduce confidence in the carrying value of parts of the portfolio. They also lower equity and indicate that prior growth assumptions will require reassessment, limiting financial resilience.
Vifor Portfolio DeclineVifor faces several structural pressures rather than a temporary sales fluctuation, including generic competition and lost product support. A projected 25% revenue decline can weigh on group growth, reduce scale benefits and require sustained portfolio remediation and investment.
Albumin Pressure In ChinaChina’s cost-containment measures and lower albumin market value create a persistent headwind for an established CSL product. Continued pricing pressure can compress margins and reduce the contribution of albumin even if volumes stabilize, making recovery dependent on market conditions and mix.
CSL News
CSL FAQ
What was CSL’s price range in the past 12 months?
CSL lowest share price was AU$90.00 and its highest was AU$221.76 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is AU$94.20B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Feb 09, 2027 which is in 110 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 17, 2026. The company reported AU$3.264 earnings per share for the quarter, missing the consensus estimate of AU$3.402 by -AU$0.137.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of AU$2.244 which represents an annual dividend yield of 2.07%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 5.78.
How many shares outstanding does CSL have?
CSL has 479,884,280 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of AU$3.264 in its last earnings report, missing expectations of AU$3.402. Following the earnings report the stock price went up 17.252%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in AU:CSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$183.75 (5.82% Upside)
AU$183.75 (5.82% Upside)
Blogger Sentiment
Bullish
AU:CSL Sentiment 81%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.49%
12-Months-Change
Fundamentals
Return on Equity
-15.12%
Trailing 12-Months
Asset Growth
-14.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CSL
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
CSL Company Deck
CSL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of stabilization and operational progress (strong cash flow, ahead-of-plan transformation savings, Ig momentum in H2, successful new product launches and Seqirus share gains) but was overshadowed by very large impairments, a statutory net loss, and significant, structural headwinds in Vifor (anticipated ~25% revenue decline) plus continued pressure on albumin. While management has a clear remediation plan and delivered early positive operational signs, the scale and persistence of the portfolio and impairment issues materially weaken near-term financial prospects.View all AU:CSL earnings summariesCSL Stock 12 Month Forecast
Average Price Target
AU$183.75
▲(5.82% Upside)
Technical Analysis
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―